The scale-X carbo integrated system for intensified upstream viral manufacturing will be used for demonstrations and training
Univercells Technologies, a provider of biomanufacturing technologies, and the National Institute of Bioprocessing Research and Training (NIBRT) in Ireland, have announced a collaboration to address the need for training in cell and gene therapies (CGTs). The intermediate capacity scale-X carbo system from Univercells will be introduced at the Dublin facility for hands-on demonstration and training.
Demand for viral vectors has grown as the clinical pipeline of CGTs continues to multiply. There are significant limitations, Univercells says, with existing technologies to support manufacturers from research to commercial phases. Anticipating the great capacity and cost constraints will require dedicated manufacturing technologies to optimise, scale-up and deliver these products. This rapid growth of CGTs together with the complexities of the manufacturing process has resulted in an urgent shortage for highly skilled CGT manufacturing staff, the company says. The intensified bioreactor will play a role in helping to upskill newcomer to expert level biopharmaceutical professionals and researchers and eventually leveraging such scalable technologies to bridge the clinical gap.
“Across the industry, developers and manufacturers are looking for next generation technologies. They require purposefully designed tools that apply the principles of intensification, integration and semi- or fully continuous processing to overcome the existing barriers to discovery and commercialization in viral manufacturing,” said CEO of Univercells Technologies, Mathias Garny.
“Our scale-X product series is a uniquely intensified and automated solution that can help to bring advanced therapies to the market using reliable, reproducible processes with increased capacity in a decreased footprint. We are honoured to have it featured at a respected institute like NIBRT and contribute to training the workforce that will drive manufacture of the advance therapies of tomorrow.”
John Milne, NIBRT Training Director commented: “We are always looking out for the latest bioprocessing innovations to accomplish our mission of supporting the biopharmaceutical industry with access to the most advanced technologies for research and training. The scale-X carbo system is the ideal intermediate-scale system to train on process development, optimisation, and scale-up principles through R&D to commercial capacity. The scale-X carbo system will help our team to deliver cutting edge training and research collaborations in viral vector development.”